Golimumab in UC sees benefits within six weeks

Two-thirds of patients receiving golimumab for moderate to severe ulcerative colitis (UC) show a significant clinical response within six weeks, according to a phase IV study in the UK.

The open-label GO-COLITIS study enrolled 205 adults (average age 39 years) who had suffered from UC for at least three months, but who had not received anti-tumour necrosis factor therapy. After the first six weeks of treatment with golimumab, 68.8 per cent of patients showed clinical responses, while 38.5 per cent entered clinical remission.

Eight per cent developed serious adverse events – usually flare or worsening (5 per cent), and accidental overdose, anaphylaxis, constipation, rectal fissure and respiratory tract infection (each less than 1 per cent). Four per cent stopped due to serious adverse events.

Recommended

Diabetes screening costs in pharmacy similar to GPs

Tramadol associated with higher mortality in OA




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.